Company intelligence / Profile preview

Transcriptogen

Girton, Cambridgeshire, United Kingdom

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Transcriptogen is a private UK oncology biotech focused on discovering and developing novel small-molecule transcription factor inhibitors for cancer. The company’s lead program, TSG1301, is described as a potential NF-kappaB inhibitor in preclinical development for pancreatic and breast cancer. Transcriptogen originated as a King’s College London spin-out and is positioned around a broader platform for targeting disease-related transcription factors with small molecules. Publicly available information suggests the company remains early stage, private, and active, with limited disclosed pipeline and financing details.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Deepbridge Capital

Beyond the preview

Go deeper on Transcriptogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcriptogen.

Explore the full profile